Identification of the Angiostatin Receptor on Human Umbilical Vein Endothelial Cells
Angiogenesis is required from the growth of solid tumors and important in the pathogenesis of tumor metastasis, diabetic retinopathy, arthritis, psoriasis, and atherosclerosis. Angiostatin, a proteolytic fragment of plasminogen, is a potent antagonist of angiogenesis and an inhibitor of endothelial cell migration and proliferation. Dr. Salvatore Pizzo, MD, Ph.D. has identified a unique angiostatin receptor on the cell surface of human umbilical vein endothelial cells, distinct from the plasminogen binding site. This novel angiostatin receptor may influence regulatory mechanisms involved in cellular proliferation and migration.
Dr. Pizzo’s laboratory has fully characterized the binding site of this angiostatin receptor. His lab has also developed an antibody that demonstrates angiostatin receptor binding, inhibitition of angiostatin binding in the presence of the antibody,
This novel angiostatin receptor is a potential target the modulation of angiogenesis with applications in treating metastatic cancer, diabetic retinopathy, and atherosclerosis